X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - DRUGS.COM - Pharma Industry News - 01/Oct 22:48

FDA Approves Dupixent for Chronic Obstructive Pulmonary Disease

TUESDAY, Oct. 1, 2024 -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic...

Articles similaires

Sorry! Image not available at this time

Dupixent Approved in the US as the First-Ever Biologic Medicine for Patients with COPD

drugs.com - 27/Sep 21:09

Paris and Tarrytown, NY, September 27, 2024. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance...

Sorry! Image not available at this time

Dupixent Approved in the US as the First-Ever Biologic Medicine for Patients with COPD

drugs.com - 27/Sep 21:09

Paris and Tarrytown, NY, September 27, 2024. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance...

Sorry! Image not available at this time

FDA Approves Cobenfy (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

drugs.com - 27/Sep 04:09

PRINCETON, N.J.--(BUSINESS WIRE)--26 September 2024-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration...

Sorry! Image not available at this time

FDA Approves Miplyffa for Treatment of Niemann-Pick Disease, Type C

drugs.com - 30/Sep 22:09

MONDAY, Sept. 30, 2024 -- The U.S. Food and Drug Administration has approved Miplyffa (arimoclomol), an oral medication for the treatment of...

Sorry! Image not available at this time

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

drugs.com - 27/Sep 04:09

PRINCETON, N.J.--(BUSINESS WIRE)--26 September 2024-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration...

Sorry! Image not available at this time

FDA Approves Bimzelx for Three New Indications

drugs.com - 26/Sep 16:09

THURSDAY, Sept. 26, 2024 -- The U.S. Food and Drug Administration has approved Bimzelx (bimekizumab-bkzx) for the treatment of adults with active...

Sorry! Image not available at this time

FDA Approves Aqneursa (levacetylleucine) for the Treatment of Niemann-Pick Disease Type C

drugs.com - 25/Sep 07:09

AUSTIN, TX, September 25, 2024– IntraBio Inc., a leader in the discovery and development of innovative drugs for rare neurodegenerative...

Sorry! Image not available at this time

Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD

zacks.com - 30/Sep 19:00

Sanofi and Regeneron's Dupixent becomes the first biologic treatment approved for COPD in the United States.

Sorry! Image not available at this time

FDA Approves Miplyffa (arimoclomol) for the Treatment of Niemann-Pick Disease Type C

drugs.com - 20/Sep 05:09

CELEBRATION, Fla., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage rare...

Sorry! Image not available at this time

FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis

drugs.com - 18/Sep 22:23

WEDNESDAY, Sept. 18, 2024 -- The U.S. Food and Drug Administration has approved Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 years and...

Les derniers communiqués